Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. E. (Edwin) Bremer

Publicaties

A Luminescence-Based Method for In Vitro Screening of Immunomodulatory Checkpoints and Therapeutics

Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOP

Ensuring CAR-T Cell Quality: In-Process Controls and Quality Control Testing

High expression of signal regulatory protein beta 2 marks a favourable prognostic AML subgroup and associates with increased sensitivity to phagocytosis

Antibody desolvation with sodium chloride and acetonitrile generates bioactive protein nanoparticles

Design of Vaterite Nanoparticles for Controlled Delivery of Active Immunotherapeutic Proteins

Direct Functionalization of Polysaccharide-Based Xylan Phenyl Carbonate Nanoparticles with Tumor Cell Specific Antibodies

Novel high-yield potato protease inhibitor panels block a wide array of proteases involved in viral infection and crucial tissue damage

Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases

VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses

Pers/media

Groningse CAR-T-celtherapie krijgt KWF-subsidie

2,6 miljoen subsidie voor revolutionair oncologie onderzoek

UMCG ontvangt grote EU-subsidie voor onderzoek naar nieuwe immuuntherapie bij kanker

Grote EU-subsidie voor UMCG voor onderzoek naar CAR-T immuuntherapie bij kanker

Nationaal Groeifonds investeert in UMCG-studies om ontwikkeling kankermedicijnen te versnellen

PR Newswire Global Biotech

Ruim 5 miljoen voor uniek Nederlands platform voor gen- en celtherapie

Ruim 5 miljoen voor cel- en gentherapie